Kiniksa Pharmaceuticals Ltd (KNSA)
19.76
-0.35
(-1.74%)
USD |
NASDAQ |
May 17, 16:00
19.76
0.00 (0.00%)
After-Hours: 20:00
Kiniksa Pharmaceuticals Gross Profit Margin (Quarterly): 60.70% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 60.70% |
December 31, 2023 | |
September 30, 2023 | 60.63% |
June 30, 2023 | 69.66% |
March 31, 2023 | 68.30% |
December 31, 2022 |
Date | Value |
---|---|
September 30, 2022 | 88.34% |
June 30, 2022 | 67.74% |
March 31, 2022 | 61.25% |
December 31, 2021 | 79.37% |
September 30, 2021 | 77.12% |
June 30, 2021 | 67.99% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
60.63%
Minimum
Sep 2023
88.34%
Maximum
Sep 2022
70.11%
Average
68.15%
Median
Gross Profit Margin (Quarterly) Benchmarks
Amicus Therapeutics Inc | 87.71% |
Geron Corp | -- |
United Therapeutics Corp | 89.24% |
Vanda Pharmaceuticals Inc | 92.75% |
TG Therapeutics Inc | 91.43% |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | 2.08% |
Return on Assets | 1.76% |
Return on Invested Capital | 2.08% |
Profit Margin (Quarterly) | -22.17% |
Operating Margin (Quarterly) | -20.71% |
Return on Net Operating Assets | 12.31% |